Subscribe to NRx Newsletter

Investor Relations

NRx Pharmaceuticals is a clinical-stage, biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company’s lead program NRX-101, is an oral, fixed dosed combination of D-cycloserine and lurasidone, which targets the brain’s NMDA receptor. Please click here for more on our clinical trial status.

NRx Pharmaceuticals (Nasdaq: NRXP), formerly NeuroRx, is now traded on the Nasdaq Global Select Exchange.

Stock Data

NRX Pharmaceuticals Inc. (NRXP)
NASDAQNRXP
NASDAQNRXP
Detailed Quote
NASDAQNRXP

Recent News

Recent News (new)

For more news and articles, visit our news page.

Press Release
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
October 23, 2024

NRx Pharmaceuticals, Inc. today announced they will be featured as a participating in the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York.

Press Release
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic
October 3, 2024

Clinic to serve as the prototype for HOPE's network of Interventional Psychiatric Clinics Nationally recognized founder to become Chief Medical Innovation Officer of HOPE, in order to implement...

Press Release
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)
September 30, 2024

Stability milestone supports submission of FDA New Drug Application by NRx for the use of intravenous ketamine to treat Suicidal Depression Ketamine is currently used off-label for this...

Bottom Global Links (above footer)
NRx Communications

Subscribe to the NRx Mailing List